PMVP — PMV Pharmaceuticals Balance Sheet
0.000.00%
- $51.78m
- -$117.68m
- 32
- 53
- 31
- 32
Annual balance sheet for PMV Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 361 | 297 | 241 | 203 | 169 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 365 | 301 | 247 | 207 | 176 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.569 | 13.2 | 20.5 | 19 | 1.55 |
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 366 | 332 | 270 | 252 | 191 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Current Liabilities | 6.41 | 12.2 | 10.8 | 14 | 14.4 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 6.41 | 23 | 24.3 | 26.5 | 15.2 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 359 | 309 | 246 | 226 | 176 |
Total Liabilities & Shareholders' Equity | 366 | 332 | 270 | 252 | 191 |
Total Common Shares Outstanding |